Literature DB >> 24696188

Aortic stiffness studies in children with Kawasaki disease: preliminary results from a follow-up study from North India.

Anand Gupta1, Surjit Singh, Anju Gupta, Deepti Suri, Manojkumar Rohit.   

Abstract

Kawasaki disease (KD) is an acute medium vessel vasculitis seen in children. Coronary artery abnormalities are the most notable long-term complications. Intravenous immunoglobulin therapy has led to significant reduction in incidence of coronary aneurysms. However, higher risk of cardiovascular disease has been noted even in those children who have never been reported to develop coronary artery aneurysms during the subacute phase. Noninvasive estimation of this cardiovascular risk is useful in initiating timely preventive strategies. Arterial stiffness has been shown to be an independent predictor of cardiovascular events in general population. This study was aimed at measuring abdominal aorta stiffness in a cohort of children with KD from North India. Thirty children diagnosed to have KD at least 5 years prior to enrollment were evaluated by echocardiography for cardiac and abdominal aorta studies. Electrocardiographs were done in all patients for QT dispersion. There was a noticeable trend toward lower aortic strain, higher pressure strain elastic modulus and normalized pressure strain elastic modulus in children in the study group, though this difference did not reach statistical significance. Mean corrected QT dispersion was significantly higher in cases compared with controls. On cardiac evaluation, none of the subjects had any residual coronary artery involvement. A trend toward lower distensibility and higher stiffness of abdominal aorta was seen in cases compared with controls, though it was not found to be statistically significant. This could be a predictor of premature atherosclerosis in long term. Significantly higher QT dispersion was seen in cases compared with controls. More multicentric studies with larger sample size and longer follow-up periods are needed to clarify this issue.

Entities:  

Mesh:

Year:  2014        PMID: 24696188     DOI: 10.1007/s00296-014-3000-8

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  25 in total

1.  Endothelial dysfunction in adult patients with a history of Kawasaki disease.

Authors:  Ayumi Niboshi; Kenji Hamaoka; Koichi Sakata; Nozomi Yamaguchi
Journal:  Eur J Pediatr       Date:  2007-03-08       Impact factor: 3.183

2.  Echo-Doppler assessment of arterial stiffness in pediatric patients with Kawasaki disease.

Authors:  Abdullah AlHuzaimi; Yahya Al Mashham; James E Potts; Astrid M De Souza; George G S Sandor
Journal:  J Am Soc Echocardiogr       Date:  2013-06-22       Impact factor: 5.251

3.  Relationship between carotid intima-media thickness and arterial stiffness in children after Kawasaki disease.

Authors:  Y-f Cheung; S J Wong; M H K Ho
Journal:  Arch Dis Child       Date:  2006-07-04       Impact factor: 3.791

4.  Coronary arterial involvement and QT dispersion in Kawasaki disease.

Authors:  M Osada; Y Tanaka; T Komai; Y Maeda; M Kitano; S Komori; K Tamura; H Sugiyama; J Yanai; S Nakazawa
Journal:  Am J Cardiol       Date:  1999-08-15       Impact factor: 2.778

5.  Age dependency of stiffness of the abdominal aorta and the mechanical properties of the aorta in Kawasaki disease in children.

Authors:  M Okubo; T Ino; K Takahashi; M Kishiro; K Akimoto; Y Yamashiro
Journal:  Pediatr Cardiol       Date:  2001 May-Jun       Impact factor: 1.655

6.  Prevalence of coronary artery abnormalities in Kawasaki disease is highly dependent on gamma globulin dose but independent of salicylate dose.

Authors:  M Terai; S T Shulman
Journal:  J Pediatr       Date:  1997-12       Impact factor: 4.406

7.  Characterization of aortic remodeling following Kawasaki disease: toward a fully developed automatic biparametric model.

Authors:  Roch L Maurice; Nagib Dahdah
Journal:  Med Phys       Date:  2012-10       Impact factor: 4.071

8.  Are patients after Kawasaki disease at increased risk for accelerated atherosclerosis?

Authors:  Brian W McCrindle; Susan McIntyre; Christopher Kim; Tammy Lin; Khosrow Adeli
Journal:  J Pediatr       Date:  2007-07-24       Impact factor: 4.406

9.  Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association.

Authors:  Jane W Newburger; Masato Takahashi; Michael A Gerber; Michael H Gewitz; Lloyd Y Tani; Jane C Burns; Stanford T Shulman; Ann F Bolger; Patricia Ferrieri; Robert S Baltimore; Walter R Wilson; Larry M Baddour; Matthew E Levison; Thomas J Pallasch; Donald A Falace; Kathryn A Taubert
Journal:  Pediatrics       Date:  2004-12       Impact factor: 7.124

10.  Echocardiographic and electrocardiographic trends in children with acute Kawasaki disease.

Authors:  Matthew A Crystal; Sumeet K Syan; Rae S M Yeung; Anne I Dipchand; Brian W McCrindle
Journal:  Can J Cardiol       Date:  2008-10       Impact factor: 5.223

View more
  4 in total

1.  Mid-term Risk for Subclinical Atherosclerosis and Chronic Myocarditis in Children with Kawasaki Disease and Transient Coronary Abnormalities.

Authors:  Mansingh Parihar; Surjit Singh; Pandiarajan Vignesh; Anju Gupta; Manojkumar Rohit
Journal:  Pediatr Cardiol       Date:  2017-05-17       Impact factor: 1.655

Review 2.  Kawasaki disease for dermatologists.

Authors:  Aman Gupta; Surjit Singh
Journal:  Indian Dermatol Online J       Date:  2016 Nov-Dec

Review 3.  An Update on Cardiovascular Risk Factors After Kawasaki Disease.

Authors:  Yuan-Yuan Zeng; Min Zhang; Syeun Ko; Feng Chen
Journal:  Front Cardiovasc Med       Date:  2021-04-16

4.  Evaluation of Arterial Functions and Carotid Intima Media Thickness in Children During Mid-Term Follow-Up After Kawasaki Disease.

Authors:  Nilüfer Çetiner; Figen Akalın; Elif Erolu; Tevfik Bayram; Goncagül Haklar
Journal:  Turk Arch Pediatr       Date:  2021-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.